Enterprise Value

642.3M

Cash

42.99M

Avg Qtr Burn

-5.652M

Short % of Float

0.04%

Insider Ownership

8.54%

Institutional Own.

1.73%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

Motixafortide (BL-8040) w/ zimberelimab Details
Pancreatic cancer, Cancer, Solid tumor/s

Phase 2/3

Data readout

Motixafortide (BL-8040) w/ cemiplimab Details
Pancreatic cancer, Solid tumor/s, Cancer

Phase 2

Data readout

AGI-134 Details
Solid tumor/s, Cancer

Phase 1/2

Update

Motixafortide (BL-8040) +/- natalizumab Details
Cancer, Blood disorder, Sickle cell disease

Phase 1

Data readout

Motixafortide (BL-8040) (CXCR4 antagonist) Details
Solid tumor/s, Pancreatic cancer, Cancer

Failed

Discontinued

Failed

Discontinued